The FDA-cleared PrecivityAD2® test is now available to order

For Health Care Professionals

Get a clear picture of brain amyloid plaques, a pathological hallmark of Alzheimer’s disease.

Laboratory scientists in masks and face shields loading blood samples into a lab instrument

Our comprehensive portfolio of clinically-validated blood tests combine high precision LC-MS/MS instruments and smart analytics to accurately determine amyloid pathology in the brain.

State-of-the-art proprietary liquid-chromatography-tandem mass spectrometry (LC-MS/MS) methodologies

Blood tests to assess for brain amyloid pathology - The PrecivityAD® and PrecivityAD2® tests

Extensive domain expertise; leading neurological scientists and researchers on staff

Why Diagnose AD

As the number of people living with AD grows, swift, precise diagnosis matters more than ever. An early AD diagnosis can empower patients to proactively manage their health, allow for independent decision-making, and ultimately enhance their quality of life. And while traditional biomarker assessments face barriers and drawbacks, high performing blood tests like PrecivityAD2® can address the need for widely accessible, equitable, and scalable testing options to aid in a timely AD diagnosis.

Learn about the clinical value of our tests

Advantages of BBM Tests

The PrecivityAD2® test was clinically validated in 583 individuals with cognitive impairment across 2 well-characterized, independent cohorts. The QUIP-II study evaluated how specialists were able to use the PrecivityAD2® test to optimize AD clinical decision-making in 203 patients from real-world settings.

Review our data and evidence

Featured Publications

View all publications
January 9, 2025

Walter S, Langford O, Jimenez-Maggiora GA, et al. The AlzMatch Pilot Study - Feasibility of remote blood collection of plasma biomarkers for preclinical Alzheimer’s disease trials.J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi.org/10.14283/jpad.2024.101

June 13, 2023

Angioni D, Hansson O, Bateman RJ, et al. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force. J Prev AlzheimersDis. 2023. doi.org/10.14283/jpad.2023.68

March 15, 2022

Schindler SE, Li Y, Li M, et al. Using Alzheimer’s disease blood tests to accelerate clinical trial enrollment. Alzheimers Dement. 2023;19(4):1175-1183. doi:10.1002/alz.12754

Health Care Professionals

Order a test

If you are interested in offering the PrecivityAD® test to your patients, please complete the form to start the process for opening a test account and a C₂N representative will be in touch with you shortly.